Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 7 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Pharmaceutical Supply Chain in Japan Overview | 9 | 21 |
| Introduction | 9 | 1 |
| Structure of Supply Chain Distribution Channels | 9 | 1 |
| Participants in Supply Chain | 10 | 1 |
| Manufacturers Pharmaceutical Companies | 10 | 1 |
| Raw Materials Procurement | 10 | 1 |
| Contract Manufacturing Organizations | 10 | 1 |
| Pharmaceutical Supply Chain Upstream and Downstream | 11 | 1 |
| Leading Pharmaceutical Companies in Japan | 12 | 1 |
| Foreign Pharmaceutical Manufacturers in Japan | 12 | 1 |
| Wholesaler | 13 | 1 |
| Wholesaler Customers | 14 | 1 |
| Leading Companies | 15 | 1 |
| Payment Terms with Manufacturers | 16 | 1 |
| Wholesaler Margins and Price Negotiations | 16 | 1 |
| Medical Institutions | 17 | 1 |
| Pharmacies | 17 | 1 |
| Dispensing Fees for Pharmacies | 17 | 1 |
| Mail Order/Internet Pharmacies | 18 | 1 |
| Hospitals | 18 | 1 |
| Patients | 18 | 1 |
| Drug Purchase Pattern | 18 | 1 |
| Doctor s Prescription | 19 | 1 |
| Reimbursement Scenario | 19 | 1 |
| Evolution of Pharmaceutical Supply Chain in Japan | 20 | 1 |
| Traditional Method | 20 | 1 |
| Ethical Drugs | 20 | 1 |
| Over-the-Counter Drugs | 21 | 1 |
| Biologics | 21 | 1 |
| New Technologies Implemented in Japanese Pharmaceutical Supply Chain | 21 | 1 |
| SMS | 21 | 1 |
| Bar Coding | 21 | 1 |
| Radiofrequency Identification | 22 | 1 |
| How Japanese Pharmaceutical Distribution Differs from that of the US and the UK | 23 | 1 |
| Supply Chain Overview | 23 | 1 |
| Downstream Supply Chain from Manufacturer | 23 | 1 |
| Logistics Outsourcing | 24 | 1 |
| Direct-to-pharmacy and Direct-to-hospital Model | 24 | 1 |
| Payment Terms for a Pharmaceutical Manufacturer | 24 | 1 |
| Role of Wholesalers | 24 | 1 |
| Wholesaler and Pharmacy Margins | 25 | 1 |
| Upstream Supply Chain for Pharmacies | 25 | 1 |
| Reimbursement Scenario | 25 | 1 |
| Business Strategies Involving Japan and India | 26 | 1 |
| Case Study of Daiichi Sankyo and Ranbaxy | 26 | 1 |
| About Daiichi Sankyo | 26 | 1 |
| About Ranbaxy Laboratories | 26 | 1 |
| Hybrid Business Model between Daiichi Sankyo and Ranbaxy | 26 | 1 |
| Supply Chain Initiatives under the Hybrid Business Model | 27 | 1 |
| Success of the Hybrid Model | 27 | 1 |
| Case Study of Lupin | 28 | 1 |
| About Lupin | 28 | 1 |
| Lupin-Kyowa Deal | 28 | 1 |
| I rom Deal | 28 | 1 |
| Supply Chain Initiatives | 28 | 1 |
| Key Highlights of Lupin in Japan | 28 | 1 |
| Growth Drivers for Lupin in Japan | 28 | 1 |
| Competitive Landscape | 29 | 1 |
| Pharmaceutical Supply Chain in Japan Laws and Regulations | 30 | 5 |
| Manufacturing License | 30 | 1 |
| Foreign Manufacturers | 30 | 1 |
| Approval Process for Accreditation of Foreign Manufacturer | 31 | 1 |
| Application for Change/Addition to Category of Accreditation of Foreign Manufacturers | 32 | 1 |
| Application for Renewal of Accreditation of Foreign Manufacturers | 32 | 1 |
| Post-marketing Safety | 32 | 1 |
| License for Marketing Authorization | 32 | 1 |
| Pharmaceuticals Labeling and Advertising Regulations | 33 | 1 |
| Drug Retail Seller Licensing | 33 | 1 |
| Good Post-marketing Surveillance Practice | 33 | 1 |
| Adverse Drug Reaction and Infection Reporting | 34 | 1 |
| Pharmaceutical Supply Chain in Japan Risk Management | 35 | 4 |
| Supply Risk | 35 | 1 |
| Imports | 35 | 1 |
| Inferior Quality of Supply | 35 | 1 |
| Non-availability of Resources | 35 | 1 |
| Natural Disasters | 36 | 1 |
| Selection of Supplier | 36 | 1 |
| Cost Risk | 36 | 1 |
| Demand Risks | 37 | 1 |
| Forecasting Errors | 37 | 1 |
| Miscellaneous Risks | 37 | 1 |
| Transportation Risk | 37 | 1 |
| Quality Risks | 37 | 1 |
| Storage Risk | 37 | 1 |
| Information Sharing Risks | 37 | 1 |
| Safety Regulations | 38 | 1 |
| Pharmaceutical Supply Chain in Japan Securing the Supply Chain | 39 | 4 |
| Pharmaceutical Supply Chain Industry Key Issues | 39 | 1 |
| Drug Price Revision | 39 | 1 |
| Inflexible Business Culture | 39 | 1 |
| Packaging Issues | 39 | 1 |
| Lack of Advanced Planning | 40 | 1 |
| Impact of Government Regulations Regarding Technology Adoption in Pharmaceutical Supply Chain | 40 | 1 |
| Case Study: Toho Pharmaceutical Co., Ltd. | 41 | 1 |
| Overview and Specifications | 41 | 1 |
| Receipt of Products | 41 | 1 |
| Automatic Transportation | 42 | 1 |
| Automated Storage | 42 | 1 |
| Sales Package Picking | 42 | 1 |
| Flashing Tags | 42 | 1 |
| Shipment | 42 | 1 |
| Summary | 42 | 1 |
| Pharmaceutical Supply Chain in Japan Drivers and Restraints | 43 | 3 |
| Drivers | 43 | 1 |
| Universal Health Coverage | 43 | 1 |
| Growing Demand for Secure Packaging | 43 | 1 |
| Japanese Pharmaceutical Industry: M&A trends | 43 | 1 |
| Globalization and Emerging Markets | 44 | 1 |
| Free Trade Agreements with Various Countries | 44 | 1 |
| Restraints | 45 | 1 |
| Drug Price Regulation | 45 | 1 |
| Counterfeit Drugs and Drug Traceability | 45 | 1 |
| High Cost of Securing Supply Chain | 45 | 1 |
| Natural Disasters | 45 | 1 |
| Pharmaceutical Supply Chain in Japan Leading Distribution Players | 46 | 9 |
| Medipal Holdings Corporation in Japan | 46 | 1 |
| Company Overview | 46 | 1 |
| Financial Performance | 47 | 1 |
| Initiatives under the 2014 Medipal Medium-term Vision | 48 | 1 |
| Enhancing the Quality of Distribution | 48 | 1 |
| Enhancing the Quality of Information Provision | 48 | 1 |
| Alfresa Holdings Corporation in Japan | 48 | 1 |
| Company Overview | 48 | 1 |
| Financial Performance | 49 | 1 |
| Suzuken Group in Japan | 50 | 1 |
| Company Overview | 50 | 1 |
| Financial Performance | 51 | 1 |
| Disaster Countermeasures Systems | 52 | 1 |
| Toho Holdings Co., Ltd. in Japan | 53 | 1 |
| Company Overview | 53 | 1 |
| Financial Performance | 54 | 1 |
| Pharmaceutical Supply Chain in Japan Appendix | 55 | 4 |
| Market Definitions | 55 | 1 |
| Abbreviations | 55 | 1 |
| Bibliography | 56 | 1 |
| Research Methodology | 57 | 2 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 58 | 1 |